chimmitecan

has antineoplastic activity; structure in first source

Networked: 4 relevant articles (0 outcomes, 2 trials/studies)

1.	Neoplasms (Cancer) 02/15/2007 - "Chimmitecan presented potent efficacy in A549 tumor model when given orally. " 11/01/2021 - "A validated HPLC-MS/MS method for determination of simmitecan and its metabolite chimmitecan in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor." 02/15/2007 - "I.v. administration of chimmitecan inhibited the growth of HCT-116, MDA-MB-435, BEL-7402, and A549 human carcinoma xenografts in nude mice, with greater potency than CPT-11 against the latter two tumors models. " 11/01/2013 - "To investigate the pharmacokinetics and disposition of simmitecan (L-P) that was a water-soluble ester prodrug of chimmitecan (L-2-Z) with potent anti-tumor activities in different experimental animals, and to assess its drug-drug interaction potential. "
2.	Colonic Neoplasms (Colon Cancer) 06/01/2008 - "In this study, the repairable double-strand breaks were induced in human colon cancer HCT116 cells by 1-h exposure to 25 or 100 nmol/L CPT and its novel derivative chimmitecan. "
3.	Leukemia 02/15/2007 - "Furthermore, nanomolar levels of chimmitecan caused impressive DNA damage, G(2)-M phase arrest, and apoptosis in human leukemia HL60 cells. "
4.	Carcinoma (Carcinomatosis) 02/15/2007 - "I.v. administration of chimmitecan inhibited the growth of HCT-116, MDA-MB-435, BEL-7402, and A549 human carcinoma xenografts in nude mice, with greater potency than CPT-11 against the latter two tumors models. "

1.	simmitecan
2.	2- cyclohexylidenhydrazo- 4- phenyl- thiazole
3.	Prodrugs
4.	Esters
5.	Irinotecan (Camptosar)